News Details

Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations

About CNS Pharmaceuticals, Inc.
  • NASDAQ: $CNSP
  • Notified: $2.00
  • 07:02 EDT

Price Chart